Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

References

1. 1.↵
   2. Casulo C,
   3. Friedberg J.

   Treating Burkitt lymphoma in adults. Curr Hematol Malig Rep. 2015;10:266–71.

   OpenUrl
2. 2.↵
   2. Mead GM,
   3. Sydes MR,
   4. Walewski J,
   5. Grigg A,
   6. Hatton CS,
   7. Norbert P, et al.

   An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264–74.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Magrath I,
   3. Adde M,
   4. Shad A,
   5. Venzon D,
   6. Seibel N,
   7. Gootenberg J, et al.

   Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925–34.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   2. Mead GM,
   3. Barrans SL,
   4. Qian W,
   5. Walewski J,
   6. Radford JA,
   7. Wolf M, et al.

   A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112:2248–60.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Evens AM,
   3. Carson KR,
   4. Kolesar J,
   5. Nabhan C,
   6. Helenowski I,
   7. Islam N, et al.

   A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol. 2013;24:3076–81.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Ribrag V,
   3. Koscielny S,
   4. Bosq J,
   5. Leguay T,
   6. Casasnovas O,
   7. Fornecker L-M, et al.

   Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402–11.

   OpenUrl
7. 7.↵
   2. Dunleavy K,
   3. Pittaluga S,
   4. Shovlin M,
   5. Steinberg SM,
   6. Cole D,
   7. Grant C, et al.

   Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–25.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   2. Zuze T,
   3. Ellis GK,
   4. Kasonkanji E,
   5. Kaimila B,
   6. Nyasosela R,
   7. Nyirenda R, et al.

   Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. Cancer Med. 2020;9:77–83.

   OpenUrl
9. 9.↵
   2. Rizzieri DA,
   3. Johnson JL,
   4. Niedzwiecki D,
   5. Lee EJ,
   6. Vardiman JW,
   7. Powell BL,
   8. Barcos M, et al.

   Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100:1438–48.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Rizzieri D,
    3. Johnson J,
    4. Byrd J,
    5. Lozanski G,
    6. Blum K,
    7. Powell B, et al.

    Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10002. Br J Haematol. 2014;165:102–11.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Cheson BD,
    3. Fisher RI,
    4. Barrington SF,
    5. Cavalli F,
    6. Schwartz LH,
    7. Zucca E, et al.

    Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Ye Z,
    3. Xiao Y,
    4. Shi H,
    5. Ke Z,
    6. Liu Y,
    7. Liang Y, et al.

    Sporadic Burkitt lymphoma in southern China: 12 years’ experience in a single institution in Guangzhou. J Clin Pathol. 2011;64:1132–5.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    2. Jacobson C,
    3. LaCasce A.

    How I treat Burkitt lymphoma in adults. Blood. 2014;124:2913–20.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    2. Costa LJ,
    3. Xavier AC,
    4. Wahlquist AE,
    5. Hill EG.

    Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013;121:4861–6.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version). Chin J Cancer Res. 2019;31:557–77.

    OpenUrl
16. 16.↵
    2. Lacasce A,
    3. Howard O,
    4. Li S,
    5. Fisher D,
    6. Weng A,
    7. Neuberg D, et al.

    Modified magrath regimens for adults with Burkitt and Burkitt-Like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761–7.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    2. Noy A,
    3. Lee JY,
    4. Cesarman E,
    5. Ambinder R,
    6. Baiocchi R,
    7. Reid E, et al.

    AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126:160–6.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    2. Corazzelli G,
    3. Frigeri F,
    4. Russo F,
    5. Frairia C,
    6. Arcamone M,
    7. Esposito G, et al.

    RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol. 2011;156:234–44.

    OpenUrlPubMed
19. 19.↵
    2. Yang X,
    3. Huang Q,
    4. Li A,
    5. Chen Y,
    6. Xu W,
    7. Li J, et al.

    A long-term retrospective study on sporadic Burkitt lymphoma in Chinese population. Medicine (Baltimore). 2020;99:e18438.